EATG » Johnson & Johnson at AIDS 2018: press releases

Johnson & Johnson at AIDS 2018: press releases

24 July 2018, 22nd International AIDS Conference (AIDS 2018), Amsterdam, the Netherlands

 

 

Phase 3 EMERALD and DIAMOND studies at AIDS 2018 reinforce the safety and efficacy of SYMTUZATM (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg), the first darunavir-based HIV-1 single-tablet regimen

 

 

In early-stage APPROACH study, mosaic-based vaccine regimen maintained robust immune response one year after last vaccination

News categories: HIV treatment, Vaccines, AIDS 2018